Ignis Therapeutics and STADA partner on apomorphine in China
China’s Ignis Therapeutics and Germany’s STADA Arzneimittel’s (SAZ: Xetra) Britannia Pharmaceuticals UK affiliate today jointly announced the signing of an exclusive licensing agreement under which Ignis Therapeutics will develop and commercialize subcutaneous apomorphine for Parkinson's disease in mainland China, Hong Kong and Macau.
Under terms of the agreement, Britannia will receive an undisclosed upfront payment, milestone payments and sales-based royalties. Further terms of the collaboration were not revealed.
Parkinson’s disease (PD) currently affects an estimated 3 million people in China, with around 150,000 new diagnoses of the progressive neurological condition every year..A registry study conducted by Stacy et al. (2008) found that 16% of total PD patients fell within the advanced category for which continuous and intermittent dopaminergic treatment could be appropriate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze